A Novel Signature Based on m6A RNA Methylation Regulators Reveals Distinct Prognostic Subgroups and Associates with Tumor Immunity of Patients with Pancreatic Neuroendocrine Neoplasms.

MLA

Chen, Xianlong, et al. “A Novel Signature Based on M6A RNA Methylation Regulators Reveals Distinct Prognostic Subgroups and Associates with Tumor Immunity of Patients with Pancreatic Neuroendocrine Neoplasms.” Neuroendocrinology, vol. 112, no. 12, Dec. 2022, pp. 1187–99. EBSCOhost, https://doi.org/10.1159/000525228.

APA

Chen, X., Mo, S., Zong, L., Yu, S., Lu, Z., & Chen, J. (2022). A Novel Signature Based on m6A RNA Methylation Regulators Reveals Distinct Prognostic Subgroups and Associates with Tumor Immunity of Patients with Pancreatic Neuroendocrine Neoplasms. Neuroendocrinology, 112(12), 1187–1199. https://doi.org/10.1159/000525228

Chicago

Chen, Xianlong, Shengwei Mo, Liju Zong, Shuangni Yu, Zhaohui Lu, and Jie Chen. 2022. “A Novel Signature Based on M6A RNA Methylation Regulators Reveals Distinct Prognostic Subgroups and Associates with Tumor Immunity of Patients with Pancreatic Neuroendocrine Neoplasms.” Neuroendocrinology 112 (12): 1187–99. doi:10.1159/000525228.